EUVIMEDEUVIMED entdecken
Crossref

Clinical and economic evaluation of extended-release metformin for the treatment of prediabetes and its impact on the budget and target indicators of federal healthcare projects

N. A. Avxentyev, O. V. Vasyukova, O. M. Drapkina, L. Yu. Drozdova, S. K. Zyryanov, E. R. Kovaleva, A. S. Makarov, Yu. V. Makarova, O. L. Rozenson, V. V. Salukhov, A. V. Sineglazova, O. Y. Sukhareva und 1 weitere

Diabetes mellitus · 18.05.2026 · 29 (2) · 169-182

DOI: 10.14341/dm13471 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes mellitus, online erschienen am 18.05.2026. Verfasst von N. A. Avxentyev und 12 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND : Patients with prediabetes have an increased risk of developing type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). However, the economic impact of using medications to treat prediabetes has been insufficiently studied. AIM: The purpose of the study is to perform a clinical and economic evaluation of extended-release (XR) metformin for the treatment of prediabetes, assess its healthcare budgetary impact, and determine its potential to contribute to achieving the target indicators of Federal healthcare programs. MATERIALS AND METHODS: We compared XR metformin therapy with no medication therapy among patients aged 40–59 years with prediabetes, for whom lifestyle interventions had failed to achieve adequate glycemic control. A Markov model was developed to describe the number of patients with prediabetes over a 10-year horizon using comparison variants, the incidence of adverse cardiovascular events, and mortality from all and cardiovascular causes. The analysis accounted for out-of-pocket expenditures for pharmacotherapy and public healthcare system costs for the management and monitoring of prediabetes and its complications, including T2DM. RESULTS : Over a 10-year period, the use of XR metformin in patients with prediabetes could prevent 63 524 deaths, including 41.6 thousand from CVD. The estimated additional annual out-of-pocket expenditures for 100% coverage with XR metformin are approximately 4.3 billion RUB. Due to reducing the incidence of T2DM and CVD, budget savings on T2DM and CVD treatment, outpatient care, and the purchase of medical devices over 10 years are estimated at 4.7 billion RUB per year. From a healthcare system perspective (public healthcare + out-of-pocket expenditures), the average net annual savings are 410 million RUB. CONCLUSION : The use of XR metformin in patients with prediabetes can reduce the rate of progression to T2D, the incidence of serious CVD events, and mortality (both all-cause and cardiovascular) and thus contribute to achieving the goals set in the federal projects "Combatting Cardiovascular Diseases" and "Combatting Diabetes Mellitus." Moreover, using XR metformin in patients with prediabetes could lead to a net reduction in public healthcare expenditures, with the long-term savings exceeding the additional costs borne by individuals for metformin therapy.

Zitieren

APA

Avxentyev, N. A., Vasyukova, O. V., Drapkina, O. M., Drozdova, L. Y., Zyryanov, S. K., Kovaleva, E. R., Makarov, A. S., Makarova, Y. V., Rozenson, O. L., Salukhov, V. V., Sineglazova, A. V., Sukhareva, O. Y., & Shestakova, M. V. (2026). Clinical and economic evaluation of extended-release metformin for the treatment of prediabetes and its impact on the budget and target indicators of federal healthcare projects. Diabetes mellitus, 29(2), 169-182. https://doi.org/10.14341/dm13471

Vancouver

Avxentyev NA, Vasyukova OV, Drapkina OM, Drozdova LY, Zyryanov SK, Kovaleva ER, et al. Clinical and economic evaluation of extended-release metformin for the treatment of prediabetes and its impact on the budget and target indicators of federal healthcare projects. Diabetes mellitus. 2026;29(2):169-182. doi:10.14341/dm13471

BibTeX
@article{Avxentyev2026,
  author = {Avxentyev, N. A. and Vasyukova, O. V. and Drapkina, O. M. and Drozdova, L. Yu. and Zyryanov, S. K. and Kovaleva, E. R. and Makarov, A. S. and Makarova, Yu. V. and Rozenson, O. L. and Salukhov, V. V. and Sineglazova, A. V. and Sukhareva, O. Y. and Shestakova, M. V.},
  title = {Clinical and economic evaluation of extended-release metformin for the treatment of prediabetes and its impact on the budget and target indicators of federal healthcare projects},
  journal = {Diabetes mellitus},
  year = {2026},
  volume = {29},
  number = {2},
  pages = {169--182},
  doi = {10.14341/dm13471}
}
Kostenlos starten →